atrial fibrillation

     

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

antiarrythmic drugs

not classified
SMART, 2002aprindineplacebonegative
AFIB, 1997bidisomideplacebonegative
P-OM3 (Kowey), 2010n-3 PUFAplacebonegative
Okishige, 2000pilsicainideplacebosuggesting
RACE II, 2010lenient rate controlstrict rate controlNCT00392613Risk of bias negative
amiodarone
Channer, 2004amiodaroneplacebosuggesting
GEFACA, 2001amiodaroneplacebosuggesting
Kochiadakis (amiodarone vs placebo), 2000amiodaroneplacebosuggesting
SAFE-T (amiodarone vs placebo), 2005amiodaroneplaceboLow risk of bias suggesting
AFFIRM Substudy (amiodarone vs class I drugs), 2003amiodaroneclass I drugsRisk of bias suggesting
AFFIRM Substudy (sotalol vs class I drugs), 2003amiodaroneclass I drugs -
Villani, 1992amiodaronedisopyramidesuggesting
Kochiadakis a, 2004amiodaronepropafenonenegative
Vitolo, 1981amiodaronequinidinesuggesting
AFFIRM Substudy (amiodarone vs sotalol), 2003amiodaronesotalolsuggesting
Kochiadakis (amiodarone vs sotalol), 2000amiodaronesotalol -
SAFE-T (amiodarone vs sotalol), 2005amiodaronesotalol -
Azimilide
ASAP, 2003Azimilideplacebonegative
disopyramide
Karlson, 1998disopyramideplacebonegative
Lloyd (Disopyramide vs placebo), 1984disopyramideplacebonegative
PRODIS, 1996disopyramidepropafenonenegative
Lloyd (Disopyramide vs quinidine), 1984disopyramidequinidine -
dofetilide
DIAMOND, 2001dofetilideplacebosuggesting
SAFIRE-D, 2000dofetilideplacebosuggesting
dronedarone
EURIDIS, 2007dronedaroneplaceboNCT00259428Low risk of bias suggesting
ADONIS, 2007dronedaroneplaceboNCT00259376Low risk of bias suggesting
DAFNE, 2003dronedaroneplacebosuggesting
EURIDIS ADONIS (pooled analysis), 2009dronedaroneplacebonegative
ATHENA, 2009dronedaroneplaceboNCT00174785Low risk of bias suggesting
PALLAS, 2011dronedaroneplaceboNCT01151137Low risk of bias negative
ERATO, 2008dronedaroneplacebo18760136Exploratory negative
DIONISOS, 2007dronedaroneamiodaroneNCT00489736suggesting
flecainide
Van Gelder, 1989flecainideno treatmentnegative
Carunchio (flecainide vs placebo), 1995flecainideplacebosuggesting
Steinbeck (flecainide vs digoxin), 1988flecainidedigoxinsuggesting
Aliot, 1996flecainidepropafenonesuggesting
Naccarelli, 1996flecainidequinidinenegative
metoprolol
Kuhlkamp, 2000metoprololplacebonegative
propafenone
Bellandi (propafenone vs placebo), 2001propafenoneplacebosuggesting
Dogan, 2004propafenoneplacebosuggesting
Kochiadakis b (propafenone vs placebo), 2004propafenoneplacebosuggesting
RAFT, 2003propafenoneplacebosuggesting
Stroobandt, 1997propafenoneplacebonegative
FAPIS, 1996propafenoneflecainidenegative
Richiardi, 1992propafenonequinidinenegative
Reimold, 1993propafenonesotalolnegative
quinidine
Hillestad, 1971quinidineno treatmentnegative
Sodermark, 1975quinidineno treatmentsuggesting
Lloyd (quinidine vs placebo), 1984quinidineplacebonegative
PAFAC (quinidine vs placebo), 2004quinidineplacebosuggesting
SOPAT (quinidine vs placebo), 2004quinidineplacebosuggesting
Byrne Quinn, 1979quinidineplacebosuggesting
Steinbeck (quinidine vs digoxin), 1988quinidinedigoxinnegative
Lloyd (quinidine vs disopyramide), 1984quinidinedisopyramide -
Steinbeck (quinidine vs flecainide), 1988quinidineflecainide -
Hohnloser, 1995quinidinesotalolnegative
Juul-Moller, 1990quinidinesotalolnegative
Kalusche, 1994quinidinesotalolnegative
SOCESP, 1999quinidinesotalolnegative
PAFAC (quinidine vs sotalol), 2004quinidinesotalol -
SOPAT (quinidine vs sotalol), 2004quinidinesotalol -
sotalol
Benditt, 1999sotalolplacebonegative
Singh, 1991sotalolplacebosuggesting
Bellandi (sotalol vs placebo), 2001sotalolplacebosuggesting
Carunchio (sotalol vs placebo), 1995sotalolplacebosuggesting
Kochiadakis (sotalol vs placebo), 2000sotalolplacebo -
Kochiadakis b (sotalol vs placebo), 2004sotalolplacebosuggesting
PAFAC (sotalol vs placebo), 2004sotalolplacebosuggesting
SAFE-T (sotalol vs placebo), 2005sotalolplacebosuggesting
SOPAT (sotalol vs placebo), 2004sotalolplacebonegative
Plewan, 2001sotalolbisoprololnegative
Carunchio (sotalol vs flecianide), 1995sotalolflecainide -
Kochiadakis b (sotalol vs propafenome), 2004sotalolpropafenone -

antithrombotics

not classified
Japanese AF Trial, 2006aspirincontrol -
EAFT, 1993oral anticoagulantplacebosuggesting
ENGAGE-AF TIMI 48 Low dose, 2013edoxaban low dosewarfarin standard doseNCT00781391Low risk of bias suggesting
phase 2 AZD0837AZD0837aspirinNCT00623779Exploratory -
NASPEAF (triflusal + coumadin medium dose vs coumadin standard dose), 2004triflusal+coumadin medium dosecoumadin standard doseRisk of bias suggesting
NASPEAF (triflusal+coumadin medium dose vs triflusal), 2004triflusal+coumadin medium dosetriflusalLow risk of bias suggesting
SIFA, 1997IndobufenwarfarinNCT00244426suggesting
Lip (phase 2 AZD0837), 2009AZD0837warfarin standard doseNCT00684307Exploratory -
EmbraceAC ongoing tecarfarinwarfarin standard dose ongoing
phase 2 YM150YM150warfarin standard doseNCT00448214Exploratory -
OPAL-2 ongoing YM150warfarin standard doseNCT00938730 ongoing
apixaban
AVERROES, 2011apixabanaspirinineligible for VKANCT00496769Low risk of bias suggesting
ARISTOTLE, 2011apixabanwarfarin standard doseNCT00412984Low risk of bias conclusive
phase 2 apixabanapixabanwarfarin standard doseNCT00787150Exploratory -
aspirin
LASAF(aspirin vs no treatment), 1999aspirincontrol -
AFASAK (aspirin vs placebo), 1989aspirinplaceboLow risk of bias negative
SPAF (aspirin,warfarin ineligible arm), 1991aspirinplaceboineligible for VKALow risk of bias negative
SPAF (aspirin , warfarin eligible arm), 1991aspirinplaceboLow risk of bias suggesting
EAFT, 1993aspirinplacebonegative
FFAACS , 2001aspirinplacebo (on top fluidione)negative
PATAF (vs coumadin low dose), 1999aspirincoumadin low doseRisk of bias negative
PATAF (vs coumadin standard dose), 1999aspirincoumadin standard doseRisk of bias negative
AFASAK II (aspirin vs warfarin low dose), 1998aspirinwarfarin low doseRisk of bias negative
SPAF II (aspirin vs warfarin standard dose, age<75), 1994aspirinwarfarin standard doseRisk of bias negative
AFASAK II (aspirin vs warfarin standard dose), 1998aspirinwarfarin standard doseRisk of bias negative
SPAF II (aspirin vs warfarin standard dose, age>75), 1994aspirinwarfarin standard doseRisk of bias negative
AFASAK (aspirin vs warfarin standard dose), 1989aspirinwarfarin standard doseRisk of bias negative
BAFTA (aspirin vs warfarin standard dose) ongoing aspirinwarfarin standard dose ongoing
clopidogrel
ACTIVE W, 2006aspirin + clopidogrelanticoagulantNCT00243178Risk of bias suggesting
ACTIVE A, 2009aspirin + clopidogrelaspirinNCT00249873Low risk of bias suggesting
coumadin
PATAF (coumadin low dose vs coumadin standard dose), 1999coumadin low dosecoumadin standard doseRisk of bias negative
dabigatran
RE-LY 110mg (2nd prevention subgroup) , 2010dabigatran 100mgwarfarinExploratory suggesting
RE-LY 150mg (2nd prevention subgroup) dabigatran 150mgwarfarinExploratory suggesting
phase 2 dabigatrandabigatranwarfarin standard doseNCT01136408Exploratory -
RE-LY (110mg), 2009dabigatran 110mgwarfarin standard doseNCT00262600Risk of bias suggesting
PETRO (150mg), 2007dabigatran 150mgwarfarin standard doseExploratory -
RE-LY (150mg), 2009dabigatran 150mgwarfarin standard doseNCT00262600Risk of bias suggesting
edoxaban
Weitz (edoxaban phase 2)edoxabanwarfarin standard doseNCT00504556Exploratory -
phase 2 edoxabanedoxabanwarfarin standard doseNCT00806624Exploratory -
ENGAGE-AF TIMI 48 High dose, 2013edoxaban high dosewarfarin standard doseNCT00781391Low risk of bias suggesting
idraparinux
AMADEUS, 2008idraparinuxwarfarin standard doseNCT00070655Risk of bias negative
idraparinux BOREALIS-AF ongoing idraparinuxwarfarin standard doseNCT00580216 ongoing
rivaroxaban
ROCKET (2nd prevention subgroup) , 2011rivaroxabanwarfarinnegative
ROCKET-AF, 2010rivaroxabanwarfarin standard doseNCT00403767Low risk of bias suggesting
ROCKET J ongoing rivaroxabanwarfarin standard doseNCT00494871 ongoing
triflusal
NASPEAF (triflusal vs coumadin standard dose)), 2004triflusalcoumadin standard doseRisk of bias negative
warfarin
BAATAF (warfarin vs no treatment), 1990warfarin low dosecontrolNCT00000517Risk of bias suggesting
SAFT(warfarin low dose + aspirin vs no treatment), 2003warfarin low dose + aspirincontrolRisk of bias negative
AFASAK (warfarin standard dose vs control), 1989warfarin standard dosecontrolRisk of bias suggesting
SPAF (warfarin standard dose), 1991warfarin standard dosecontrolRisk of bias suggesting
SPINAF (warfarin vs placebo), 1992warfarin low doseplaceboLow risk of bias negative
CAFA, 1991warfarin standard doseplaceboLow risk of bias negative
AFASAK II (warfarin low dose+aspirin vs warfarin standard dose), 1998warfarin + aspirinwarfarin standard doseRisk of bias negative
SPAF III, 1996warfarin + aspirinwarfarin standard doseRisk of bias -
AFASAK II (warfarin low dose vs warfarin standard dose), 1998warfarin low dosewarfarin standard doseRisk of bias negative
MWNAF, 1998warfarin low dosewarfarin standard doseRisk of bias negative
ximelagatran
SPORTIF II (ximelagatran vs warfarin standard dose), 2002ximelagatranwarfarin standard doseRisk of bias -
SPORTIF III, 2003ximelagatranwarfarin standard doseRisk of bias suggesting
SPORTIF V, 2005ximelagatranwarfarin standard doseLow risk of bias suggesting

catheter ablation

catheter ablation
A4 (Jais), 2008catheter ablationcontrolNCT00540787Risk of bias suggesting
Wazni , 2005catheter ablationcontrolRisk of bias suggesting
APAF (Pappone), 2006catheter ablationcontrolRisk of bias suggesting
CAFCOAF (Stabile), 2006catheter ablationcontrolRisk of bias suggesting
Krittayaphong, 2003catheter ablationcontrolRisk of bias suggesting
ThermoCool AF, 2008catheter ablationcontrolNCT00116428Risk of bias suggesting
Oral, 2006catheter ablationcontrolLow risk of bias suggesting
Forleo, 2009catheter ablationcontrolRisk of bias suggesting
Lakkireddy, 2006catheter ablationcontrolRisk of bias -
RESOLVE-AF ongoing catheter ablationcontrolNCT00111488Risk of bias ongoing
MANTRA-PAF ongoing catheter ablationcontrolNCT00133211Risk of bias ongoing
CABANA ongoing catheter ablationcontrolNCT00911508).Risk of bias ongoing

direct antithrombins

dabigatran
RE-LY (110mg), 2009dabigatran 110mgwarfarin standard doseNCT00262600Risk of bias suggesting
PETRO (150mg), 2007dabigatran 150mgwarfarin standard doseExploratory -
RE-LY (150mg), 2009dabigatran 150mgwarfarin standard doseNCT00262600Risk of bias suggesting
ximelagatran
SPORTIF II (ximelagatran vs warfarin standard dose), 2002ximelagatranwarfarin standard doseRisk of bias -
SPORTIF III, 2003ximelagatranwarfarin standard doseRisk of bias suggesting
SPORTIF V, 2005ximelagatranwarfarin standard doseLow risk of bias suggesting

direct factor Xa inhibitors

not classified
ENGAGE-AF TIMI 48 Low dose, 2013edoxaban low dosewarfarin standard doseNCT00781391Low risk of bias suggesting
phase 2 YM150YM150warfarin standard doseNCT00448214Exploratory -
OPAL-2 ongoing YM150warfarin standard doseNCT00938730 ongoing
apixaban
AVERROES, 2011apixabanaspirinineligible for VKANCT00496769Low risk of bias suggesting
ARISTOTLE, 2011apixabanwarfarin standard doseNCT00412984Low risk of bias conclusive
phase 2 apixabanapixabanwarfarin standard doseNCT00787150Exploratory -
edoxaban
Weitz (edoxaban phase 2)edoxabanwarfarin standard doseNCT00504556Exploratory -
phase 2 edoxabanedoxabanwarfarin standard doseNCT00806624Exploratory -
ENGAGE-AF TIMI 48 High dose, 2013edoxaban high dosewarfarin standard doseNCT00781391Low risk of bias suggesting
rivaroxaban
ROCKET-AF, 2010rivaroxabanwarfarin standard doseNCT00403767Low risk of bias suggesting
ROCKET J ongoing rivaroxabanwarfarin standard doseNCT00494871 ongoing

direct oral anticoagulant (DAO)

not classified
ENGAGE-AF TIMI 48 Low dose, 2013edoxaban low dosewarfarin standard doseNCT00781391Low risk of bias suggesting
phase 2 AZD0837AZD0837aspirinNCT00623779Exploratory -
Lip (phase 2 AZD0837), 2009AZD0837warfarin standard doseNCT00684307Exploratory -
phase 2 YM150YM150warfarin standard doseNCT00448214Exploratory -
OPAL-2 ongoing YM150warfarin standard doseNCT00938730 ongoing
apixaban
ARISTOTLE, 2011apixabanwarfarin standard doseNCT00412984Low risk of bias conclusive
phase 2 apixabanapixabanwarfarin standard doseNCT00787150Exploratory -
dabigatran
phase 2 dabigatrandabigatranwarfarin standard doseNCT01136408Exploratory -
RE-LY (110mg), 2009dabigatran 110mgwarfarin standard doseNCT00262600Risk of bias suggesting
PETRO (150mg), 2007dabigatran 150mgwarfarin standard doseExploratory -
RE-LY (150mg), 2009dabigatran 150mgwarfarin standard doseNCT00262600Risk of bias suggesting
edoxaban
Weitz (edoxaban phase 2)edoxabanwarfarin standard doseNCT00504556Exploratory -
phase 2 edoxabanedoxabanwarfarin standard doseNCT00806624Exploratory -
ENGAGE-AF TIMI 48 High dose, 2013edoxaban high dosewarfarin standard doseNCT00781391Low risk of bias suggesting
idraparinux
AMADEUS, 2008idraparinuxwarfarin standard doseNCT00070655Risk of bias negative
idraparinux BOREALIS-AF ongoing idraparinuxwarfarin standard doseNCT00580216 ongoing
rivaroxaban
ROCKET-AF, 2010rivaroxabanwarfarin standard doseNCT00403767Low risk of bias suggesting
ROCKET J ongoing rivaroxabanwarfarin standard doseNCT00494871 ongoing
ximelagatran
SPORTIF II (ximelagatran vs warfarin standard dose), 2002ximelagatranwarfarin standard doseRisk of bias -
SPORTIF III, 2003ximelagatranwarfarin standard doseRisk of bias suggesting
SPORTIF V, 2005ximelagatranwarfarin standard doseLow risk of bias suggesting

embolic protection

not classified
PROTECT-AFWatchmanwarfarinNCT00129545negative

prevention

not classified
TRACE (AF ancillary study), 1999trandolaprilplacebosuggesting
atorvastatin
Ozaydin, 2006atorvastatincontrolExploratory suggesting
Almroth, 2009atorvastatin placeboRisk of bias suggesting
MIRACL (sub-group) (Schwartz), 2004atorvastatinplaceboExploratory suggesting
Dernellis, 2006atorvastatinplaceboExploratory suggesting
ARMYDA-3 (AF ancillary study), 2006atorvastatinplacebosuggesting
Chello, 2006atorvastatinplaceboExploratory negative
MIRACL (AF ancillary study), 2001atorvastatinplaceboExploratory negative
STOP-AF ongoing atorvastatinplaceboNCT00252967 ongoing
candesartan
CAPRAF (Tveit), 2007candesartanplaceboNCT00130975Risk of bias -
CHARM (AF ancillary study), 2005candesartanplacebosuggesting
enalapril
Ueng, 2003enalaprilcontrolsuggesting
SOLVD (AF ancillary study), 2003enalaprilplacebosuggesting
gemfibrozil
VA HIT (AF ancillary study), 1999gemfibrozilplaceboExploratory negative
irbesartan
Madrid, 2002irbesartancontrolsuggesting
ACTIVE I, 2009irbesartanplaceboNCT00249795Low risk of bias suggesting
lisinopril
Van den Burg, 1995lisinoprilplacebonegative
GISSI-3 (AF ancillary study), 2003lisinoprilplacebonegative
losartan
LIFE (AF ancillary study), 2005losartanatenololsuggesting
olmesartan
ANTIPAF ongoing olmesartanplaceboNCT00098137Low risk of bias ongoing
pravastatin
Tveit, 2004pravastatincontrolExploratory negative
ramipril
Brown ongoing ramiprilplaceboNCT00141778 ongoing
rosuvastatin
GISSI HF (subgroup and ancillary study), 2009rosuvastatin placeboNCT00336336Exploratory negative
valsartan
GISSI-AF (Disertori), 2009valsartanplaceboNCT00376272Low risk of bias negative
Val-HeFT (AF ancillary study), 2003valsartanplacebosuggesting

rate control

not classified
Hot cafe (rate vs rythm control), 2004rate controlelectrical cardioversionnegative
RACE (rate vs rythm control), 2002rate controlelectrical cardioversionnegative
STAF (rate vs rythm control), 2003rate controlelectrical cardioversionnegative
AFFIRM (rate vs rythm control), 2002rate controlpharmacological cardioversionNCT00000556suggesting
PIAF (rate vs rythm control), 2000rate controlpharmacological cardioversionsuggesting
AF-CHF (rate vs rythm control), 2002rate controlpharmacological cardioversionNCT00597077 -
RACE II, 2010lenient rate controlstrict rate controlNCT00392613Risk of bias negative

rythm control

not classified
P-OM3 (Kowey), 2010n-3 PUFAplacebonegative
Hot cafe, 2004electrical cardioversionrate controlRisk of bias suggesting
RACE, 2002electrical cardioversionrate controlRisk of bias suggesting
STAF, 2003electrical cardioversionrate controlRisk of bias suggesting
J-RHYTHM ongoing electrical cardioversionrate control ongoing
AFFIRM, 2002pharmacological cardioversionrate controlNCT00000556Risk of bias negative
PIAF, 2000pharmacological cardioversionrate controlRisk of bias negative
AF-CHF, 2002pharmacological cardioversionrate controlNCT00597077Risk of bias -